JP2015501822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501822A5 JP2015501822A5 JP2014546468A JP2014546468A JP2015501822A5 JP 2015501822 A5 JP2015501822 A5 JP 2015501822A5 JP 2014546468 A JP2014546468 A JP 2014546468A JP 2014546468 A JP2014546468 A JP 2014546468A JP 2015501822 A5 JP2015501822 A5 JP 2015501822A5
- Authority
- JP
- Japan
- Prior art keywords
- lipocalin mutein
- pharmaceutical composition
- mutein
- composition according
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000019298 Lipocalin Human genes 0.000 claims 21
- 108050006654 Lipocalin Proteins 0.000 claims 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 8
- 229910052742 iron Inorganic materials 0.000 claims 8
- 208000007502 anemia Diseases 0.000 claims 7
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 5
- 102000018511 hepcidin Human genes 0.000 claims 5
- 108060003558 hepcidin Proteins 0.000 claims 5
- 229940066919 hepcidin Drugs 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229920001515 polyalkylene glycol Polymers 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 239000004698 Polyethylene Substances 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- -1 polyethylene Polymers 0.000 claims 2
- 229920000573 polyethylene Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 208000020459 Anaemia of malignant disease Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569501P | 2011-12-12 | 2011-12-12 | |
| US61/569,501 | 2011-12-12 | ||
| US201261599152P | 2012-02-15 | 2012-02-15 | |
| US61/599,152 | 2012-02-15 | ||
| PCT/EP2012/075135 WO2013087654A2 (en) | 2011-12-12 | 2012-12-12 | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018039343A Division JP2018118980A (ja) | 2011-12-12 | 2018-03-06 | 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501822A JP2015501822A (ja) | 2015-01-19 |
| JP2015501822A5 true JP2015501822A5 (2) | 2016-02-04 |
| JP6305345B2 JP6305345B2 (ja) | 2018-04-04 |
Family
ID=47552958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546468A Expired - Fee Related JP6305345B2 (ja) | 2011-12-12 | 2012-12-12 | 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 |
| JP2018039343A Pending JP2018118980A (ja) | 2011-12-12 | 2018-03-06 | 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018039343A Pending JP2018118980A (ja) | 2011-12-12 | 2018-03-06 | 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9610356B2 (2) |
| EP (2) | EP2791684B1 (2) |
| JP (2) | JP6305345B2 (2) |
| CN (1) | CN103998937A (2) |
| AU (1) | AU2012350654C1 (2) |
| CA (1) | CA2858959A1 (2) |
| DK (1) | DK2791684T3 (2) |
| SG (2) | SG11201402996WA (2) |
| WO (1) | WO2013087654A2 (2) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168209A (zh) * | 2015-09-21 | 2015-12-23 | 浙江大学 | HDAC1抑制剂在制备调控hepcidin表达药物中的应用 |
| CN105726543A (zh) * | 2016-02-22 | 2016-07-06 | 浙江大学 | 腺嘌呤在制备调控hepcidin表达药物中的应用 |
| JP6432962B2 (ja) * | 2016-03-29 | 2018-12-05 | 株式会社国際電気通信基礎技術研究所 | 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法 |
| MA46046A (fr) * | 2016-08-29 | 2019-07-03 | Regeneron Pharma | Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire |
| EP3946417A1 (en) * | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| JP2023117892A (ja) * | 2022-02-14 | 2023-08-24 | 公益財団法人 鷹揚郷 | ヘプシジン結合ペプチド |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US8598317B2 (en) * | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| US20090173876A1 (en) | 2006-07-21 | 2009-07-09 | Amgen Inc. | Method of detecting and/or measuring hepcidin in a sample |
| TW201307390A (zh) * | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| AR069062A1 (es) | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| WO2009094551A1 (en) | 2008-01-25 | 2009-07-30 | Amgen Inc. | Ferroportin antibodies and methods of use |
| US9315577B2 (en) | 2008-05-01 | 2016-04-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| EP2328931B1 (en) | 2008-08-06 | 2013-08-14 | Eli Lilly And Company | Anti-hepcidin-25 selective antibodies and uses thereof |
| EP2330897A4 (en) | 2008-09-18 | 2013-11-27 | Univ Columbia | NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS |
| NZ594343A (en) * | 2009-03-25 | 2013-10-25 | Genentech Inc | Novel anti-alpha5beta1 antibodies and uses thereof |
| CA2798713A1 (en) * | 2010-05-10 | 2011-11-17 | Intrinsic Lifesciences Llc | Markers for acute kidney injury |
| WO2011149962A1 (en) * | 2010-05-24 | 2011-12-01 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
| EP3299386A1 (en) | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
-
2012
- 2012-12-12 AU AU2012350654A patent/AU2012350654C1/en not_active Ceased
- 2012-12-12 WO PCT/EP2012/075135 patent/WO2013087654A2/en not_active Ceased
- 2012-12-12 EP EP12813294.1A patent/EP2791684B1/en not_active Not-in-force
- 2012-12-12 SG SG11201402996WA patent/SG11201402996WA/en unknown
- 2012-12-12 DK DK12813294.1T patent/DK2791684T3/da active
- 2012-12-12 SG SG10201604574UA patent/SG10201604574UA/en unknown
- 2012-12-12 CA CA2858959A patent/CA2858959A1/en not_active Abandoned
- 2012-12-12 EP EP17187016.5A patent/EP3309555A3/en not_active Withdrawn
- 2012-12-12 JP JP2014546468A patent/JP6305345B2/ja not_active Expired - Fee Related
- 2012-12-12 CN CN201280061110.8A patent/CN103998937A/zh active Pending
- 2012-12-12 US US14/364,465 patent/US9610356B2/en not_active Expired - Fee Related
-
2017
- 2017-02-16 US US15/435,146 patent/US9950034B2/en not_active Expired - Fee Related
-
2018
- 2018-03-06 JP JP2018039343A patent/JP2018118980A/ja active Pending
- 2018-03-28 US US15/938,117 patent/US20180311311A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501822A5 (2) | ||
| JP6305345B2 (ja) | 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 | |
| Xiao et al. | Lipocalin 2: an emerging player in iron homeostasis and inflammation | |
| US20250109183A1 (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| JP7320943B2 (ja) | 抗体含有製剤 | |
| EP3277711B1 (en) | Designed ankyrin repeat domains with binding specificity for serum albumin | |
| ES2424242T3 (es) | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos | |
| JP7395479B2 (ja) | 免疫抑制なしにｉｌ－６媒介性炎症を処置する方法 | |
| JP2016537340A5 (2) | ||
| JP2014519484A (ja) | ＴＮＦＲ：Ｆｃ融合タンパク質の安定した医薬液剤 | |
| KR102416078B1 (ko) | 항체 함유 제제 | |
| EP3452076A1 (en) | Methods, regimens, combinations & antagonists | |
| JP2017524675A5 (2) | ||
| JP2023538533A (ja) | 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１ | |
| JP7697959B2 (ja) | Ｉｌ－２タンパク質とｃｄ８０タンパク質を含む融合タンパク質製剤 | |
| JP6578546B2 (ja) | Ｌｔ阻害４価ペプチドおよびｅｔｅｃ感染症治療薬 | |
| HK40121340A (zh) | 含抗体制剂 |